drugset / Trial / NCT00195104
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out the effectiveness and side effects of arsenic trioxide in combination with low-dose ara-C.
Timeline
- Start
- 2003-09-17
- Primary completion
- 2006-03-17
- Completion
- 2006-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 5 mg/m2 | Subcutaneous |
| Subject | Cytarabine | Small molecule | 7.5 mg/m2 | Subcutaneous |
| Subject | Cytarabine | Small molecule | 10 mg/m2 | Subcutaneous |
| Subject | arsenic trioxide | Small molecule | 0.25 mg/kg | Intravenous |